<< Вернуться к списку статей журнала

Том 16 №2 2014 год - Нефрология и диализ

Возможности диетического контроля гиперфосфатемии при ХБП (Обзор литературы)

Ермоленко В.М. Филатова Н.Н.

Аннотация: В обзоре литературы приводятся данные о возможностях диетической коррекции гиперфосфатемии у больных с ХБП на заместительной почечной терапии и на преддиализных стадиях нефропатий. Основное внимание уделяется выбору продуктов с низким соотношением фосфата к белку (Pi/P, мг/г), роли пищевых добавок и лекарственного уменьшения абсорбции фосфата в желудочно-кишечном тракте.

Для цитирования: Ермоленко В.М., Филатова Н.Н. Возможности диетического контроля гиперфосфатемии при ХБП (Обзор литературы). Нефрология и диализ. 2014. 16(2):228-235. doi:

Весь текст

Ключевые слова: гиперфосфатемия, диета, хроническая болезнь почек, hyperphosphatemia, dietary control, chronic kidney disease

Список литературы:

1. Земченков А.Ю., Герасимчук Р.П., Вишневский К.А., Земченков Г.А. Гиперфосфатемия у пациентов с хронической болезнью почек на диализе: риски и возможности коррекции // Клиническая нефрология. 2013. N 4. С. 13-20.
2. Adeney K.L., Siscovick D.S., Ix J.H. et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD // J Am Soc Nephrol. 2009. Vol. 20. P. 381-387.
3. Altschul R., Hoffer A., Stephen J.D. Influence of nicotinic acid on serum cholesterol in man // Arch Biochem Biophys. 1955. Vol. 54. P. 558-589.
4. Barsotti G., Morelli E., Giannoni A. et al. Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: a controlled trial // Kidney Int Suppl. 1983. Vol. 16. P. S278-284.
5. Bell R.R., Draper H.H., Tzeng D.Y. et al. Physiological responses of human adults to foods containing phosphate additives // J Nutr. 1977. Vol. 107. P. 42-50.
6. Block G.A., Klassen P.S., Lazarus J.M. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis // J Am Soc Nephrol. 2004. Vol. 15. P. 2208-2218.
7. Boaz M., Smetana S. Regression equation predicts dietary phosphorus intake from estimate of dietary protein intake // J Am Diet Assoc. 1996. Vol. 96. P. 1268-1270.
8. Bohn L., Meyer A.S., Rasmussen S.K. Phytate: impact on environment and human nutrition. A challenge for molecular breeding // J Zhejiang Univ Sci B. 2008. Vol. 9. P. 165-191.
9. Calvo M.S., Park Y.K. Changing phosphorus content of the U.S. diet: potential for adverse effects on bone // J Nutr. 1996. Vol. 126 (Suppl 4). P. 1168S-1180S.
10. Cannata-Andía J.B., Fernández-Martín J.L., Locatelli F. et al. Use of phosphate-binding agents is associated with a lower risk of mortality // Kidney Int. 2013. Vol. 84. P. 998-1008.
11. Cheng S.C., Young D.O., Huang Y. et al. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients // Clin J Am Soc Nephrol. 2008. Vol. 3. P. 1131-1138.
12. Chiu Y.W., Teitelbaum I., Misra M. et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients // Clin J Am Soc Nephrol. 2009. Vol. 4. P. 1089-1096.
13. Cozzolino M., Gentile G., Mazzaferro S. et al. Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis // Am J Kidney Dis. 2013. Vol. 62. P. 984-992.
14. Craver L., Marco M.P., Sarro F. et al. Mineral metabolism influences pulse pressure increase provoked by chronic kidney disease // Clin Nephrol. 2007. Vol. 68. P. 87-92.
15. Dwyer J.P., Sika M., Schulman G. et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial // Am J Kidney Dis. 2013. Vol. 61. P. 759-766.
16. Edalat-Nejad M., Zameni F., Talaiei A. The effect of niacin on serum phosphorus levels in dialysis patients // Indian J Nephrol. 2012. Vol. 22. P. 174-178.
17. Eto N., Miyata Y., Ohno H., Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure // Nephrol Dial Transplant. 2005. Vol. 20. P. 1378-1384.
18. Fang Y., Ginsberg C., Sugatani T. et al. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification // Kidney Int. 2014. Vol. 85. P. 142-150.
19. Finch J.L., Lee D.H., Liapis H. et al. Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification // Kidney Int. 2013. Vol. 84. P. 1145-1153.
20. Foley R.N. Phosphate levels and cardiovascular disease in the general population // Clin J Am Soc Nephrol. 2009. Vol. 4. P. 1136-1139.
21. Gutzwiller J.P., Schneditz D., Huber A.R. et al. Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose // Nephrol Dial Transplant. 2002. Vol. 17. P. 1037-1044.
22. Hruska K.A., Mathew S., Lund R. et al. Hyperphosphatemia of chronic kidney disease // Kidney Int. 2008. Vol. 74. P. 148-157.
23. Huang X., Jiménez-Moleón J.J., Lindholm B. et al. Mediterranean diet, kidney function, and mortality in men with CKD // Clin J Am Soc Nephrol. 2013. Vol. 8. P. 1548-1555.
24. Ibels L.S., Alfrey A.C., Haut L., Huffer W.E. Preservation of function in experimental renal disease by dietary restriction of phosphate // N Engl J Med. 1978. Vol. 19. P. 122-126.
25. Isakova T., Gutiérrez O.M., Chang Y. et al. Phosphorus binders and survival on hemodialysis // J Am Soc Nephrol. 2009. Vol. 20. P. 388-396.
26. Isakova T., Wahl P., Vargas G.S. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease // Kidney Int. 2011. Vol. 79. P. 1370-1378.
27. Isakova T., Wolf M.S. FGF23 or PTH: which comes first in CKD? // Kidney Int. 2010. Vol. 78. P. 947-949.
28. Kalantar-Zadeh K., Gutekunst L., Mehrotra R. et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease // Clin J Am Soc Nephrol. 2010. Vol. 5. P. 519-30.
29. Kalantar-Zadeh K., Kuwae N., Regidor D.L. et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients // Kidney Int. 2006. Vol. 70. P. 771-780.
30. Karamanidou C., Clatworthy J., Weinman J., Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease // BMC Nephrol. 2008. Vol. 9. P. 2.
31. Karp H.J., Vaihia K.P., Kärkkäinen M.U. et al. Acute effects of different phosphorus sources on calcium and bone metabolism in young women: a whole-foods approach // Calcif Tissue Int. 2007. Vol. 80. P. 251-258.
32. Katai K., Tanaka H., Tatsumi S. et al. Nicotinamide inhibits sodium-dependent phosphate co-transport activity in rat small intestine // Nephrol Dial Transplant. 1999. Vol. 14. P. 1195-1201.
33. Kayne L.H., D’Argenio D.Z., Meyer J.H. et al. Analysis of segmental phosphate absorption in intact rats. A compartmental analysis approach // J Clin Invest. 1993. Vol. 91. P. 915-922.
34. Kooienga L. Phosphorus balance with daily dialysis // Semin Dial. 2007. Vol. 20. P. 342-345.
35. Kopple J.D., Massry S.G. Kopple and Massry’s Nutritional Management of Renal Disease // 2nd ed. Philadelphia. PA: Lippincott Williams & Wilkins, 2004.
36. Leon J.B., Sullivan C.M., Sehgal A.R. The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores // J Ren Nutr. 2013. Vol. 23. P. 265-270.
37. Leypoldt J.K., Agar B.U., Akonur A. et al. Determinants of phosphorus mobilization during hemodialysis // Kidney Int. 2013. Vol. 84. P. 841-848.
38. Lynch K.E., Lynch R., Curhan G.C., Brunelli S.M. Prescribed dietary phosphate restriction and survival among hemodialysis patients // Clin J Am Soc Nephrol. 2011. Vol. 6. P. 620-629.
39. Maccubbin D., Tipping D., Kuznetsova O. et al. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial // Clin J Am Soc Nephrol. 2010. Vol. 5. P. 582-589.
40. Manley H.J., Garvin C.G., Drayer D.K. et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider // Nephrol Dial Transplant. 2004. Vol. 19. P. 1842-1848.
41. Mayne T.J., Benner D., Ricketts K. et al. Results of a pilot program to improve phosphorus outcomes in hemodialysis patients // J Ren Nutr. 2012. Vol. 22. P. 472-479.
42. Moe S.M., Zidehsarai M.P., Chambers M.A. et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease // Clin J Am Soc Nephrol. 2011. Vol. 6. P. 257-264.
43. Müller D., Mehling H., Otto B. et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients // Clin J Am Soc Nephrol. 2007. Vol. 2. P. 1249-1254.
44. Murtaugh M.A., Filipowicz R., Baird B.C. et al. Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III // Nephrol Dial Transplant. 2012. Vol. 27. P. 990-996.
45. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease // Am J Kidney Dis. 2003. Vol. 42 (4 Suppl 3). P. S1-201.
46. Naveh-Many T., Bell O., Silver J., Kilav R. Cis and trans acting factors in the regulation of parathyroid hormone (PTH) mRNA stability by calcium and phosphate // FEBS Lett. 2002. Vol. 529. P. 60-64.
47. Noori N., Kalantar-Zadeh K., Kovesdy C.P. et al. Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients // Clin J Am Soc Nephrol. 2010. Vol. 5. P. 683-692.
48. Penne E.L., van der Weerd N.C., Grooteman M.P. et al. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients // Clin J Am Soc Nephrol. 2011. Vol. 6. P. 281-289.
49. Piccoli G.B., Ferraresi M., Deagostini M.C. et al. Vegetarian low-protein diets supplemented with keto analogues: a niche for the few or an option for many? // Nephrol Dial Transplant. 2013. Vol. 28. P. 2295-2305.
50. Sampathkumar K. Niacin and analogs for phosphate control in dialysis--perspective from a developing country // Int Urol Nephrol. 2009. Vol. 41. P. 913-918.
51. Sampathkumar K., Selvam M., Sooraj Y.S. et al. Extended release nicotinic acid - a novel oral agent for phosphate control // Int Urol Nephrol. 2006. Vol. 38. P. 171-174.
52. Sampathkumar K., Sooraj Y.S., Ajeshkumar R.P. Extended release nicotinic acid is a promising agent for phosphate control in hemodialysis // Kidney Int. 2006. Vol. 69. P. 1281.
53. Sandberg A.S., Andersson H., Kivistö B., Sandström B. Extrusion cooking of a high-fibre cereal product. 1. Effects on digestibility and absorption of protein, fat, starch, dietary fiber and phytate in the small intestine // Br J Nutr. 1986. Vol. 55. P. 245-254.
54. Schiavi S.C., Tang W., Bracken C. et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD // J Am Soc Nephrol. 2012. Vol. 23. P. 1691-1700.
55. Sherman R.A., Mehta O. Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources // Am J Kidney Dis. 2009. Vol. 54. P. 18-23.
56. Shinaberger C.S., Greenland S., Kopple J.D. et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? // Am J Clin Nutr. 2008. Vol. 88. P. 1511-1518.
57. Shinaberger C.S., Kilpatrick R.D., Regidor D.L. et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients // Am J Kidney Dis. 2006. Vol. 48. P. 37-49.
58. Slatopolsky E., Robson A.M., Elkan I., Bricker N.S. Control of phosphate excretion in uremic man. // J Clin Invest. 1968. Vol. 47. P. 1865-1874.
59. Spalding E.M., Chamney P.W., Farrington K. Phosphate kinetics during hemodialysis: Evidence for biphasic regulation // Kidney Int. 2002. Vol. 61. P. 655-667.
60. Speer T., Zewinger S., Fliser D. Uraemic dyslipidaemia revisited: role of high-density lipoprotein // Nephrol Dial Transplant. 2013. Vol. 28. P. 2456-2463.
61. Sullivan C., Sayre S.S., Leon J.B. et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial // JAMA. 2009. Vol. 301. P. 629-635.
62. Sullivan C.M., Leon J.B., Sehgal A.R. Phosphorus-containing food additives and the accuracy of nutrient databases: implications for renal patients // J Ren Nutr. 2007. Vol. 17. P. 350-354.
63. Takahashi Y., Tanaka A., Nakamura T. et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients // Kidney Int. 2004. Vol. 65. P. 1099-1104.
64. Taylor L.M., Kalantar-Zadeh K., Markewich T. et al. Dietary egg whites for phosphorus control in maintenance haemodialysis patients: a pilot study // J Ren Care. 2011. Vol. 37. P. 16-24.
65. Tenenhouse H.S. Regulation of phosphorus homeostasis by the type IIa Na/phosphate co-transporter // Annu Rev Nutr. 2005. Vol. 25. P. 197-214.
66. Tentori F., Blayney M.J., Albert J.M. et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS) // Am J Kidney Dis. 2008. Vol. 52. P. 519-530.
67. The USRDS Dialysis Morbidity and Mortality Study: Wave 2. United States Renal Data System // Am J Kidney Dis. 1997. Vol. 30 (2 Suppl 1). P. S67-85.
68. Tomiyama C, Higa A, Dalboni MA et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients // Nephrol Dial Transplant. 2006. Vol. 21. P. 2464-2471.
69. Tonelli M., Pannu N., Manns B. Oral phosphate binders in patients with kidney failure // N Engl J Med. 2010. Vol. 362. P. 1312-1324.
70. Tonelli M., Sacks F., Pfeffer M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease // Circulation. 2005. Vol. 112. P. 2627-2633.
71. Uribarri J. Phosphorus additives in food and their effect in dialysis patients // Clin J Am Soc Nephrol. 2009. Vol. 4. P. 1290-1292.
72. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease // J Am Soc Nephrol. 2010. Vol. 21. P. 1427-1435.
73. Wüthrich R.P., Chonchol M., Covic A. et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients // Clin J Am Soc Nephrol. 2013. Vol. 8. P. 280-289.
74. Young D.O., Cheng S.C., Delmez J.A., Coyne D.W. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients // Perit Dial Int. 2009. Vol. 29. P. 562-567.
75. Zoccali C., Ruggenenti P., Perna A. et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition // J Am Soc Nephrol. 2011. Vol. 22. P. 1923-1930.

Другие статьи по теме

• Гиперпаратиреоз и минеральная плотность кости у больных с хронической болезнью почек: влияние паратиреоидэктомии
• Особенности проведения заместительной почечной терапии у больного гемофилией А
• Современные тенденции коррекции гиперфосфатемии у больных хронической болезнью почек. Обзор литературы
• Гиперпаратиреоз и хроническая болезнь почек. Часть 2. Современные подходы к профилактике и лечению вторичного гиперпаратиреоза. Лекция